A Study on the Changes and Prognosis of Intestinal Microbiota and Function in Infants With Food Allergies
NCT ID: NCT06854536
Last Updated: 2025-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
100 participants
OBSERVATIONAL
2025-02-01
2028-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Bifidobacterium Intervention in Food Allergic Infants
NCT05965063
Metagenomic Analysis of Gut Microbiome in Preterm
NCT03235635
Study to Evaluate the Effects of a Formula on the Gut Health of Healthy Chinese Infants and Young Children
NCT04864665
The Impact of a Prebiotics and Lactoferrin Containing Infant Formula on Stool Characteristics in Healthy Term Infants
NCT02363582
Feeding the Preterm Gut Microbiota - Impact of Infant-feeding on Preterm Gut Microbiota Development
NCT03663556
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The pathogenesis of FA is not yet fully understood, but increasing evidence supports the involvement of abnormal gut microbiota in the pathophysiology of FA. Extensive basic research has found that certain probiotics play roles at multiple stages in the development of food allergies, including: In the intestinal lumen: regulating the structure of gut microbiota, increasing the production of secretory IgA, and modifying antigen peptides. At the intestinal mucosal level: improving intestinal mucosal permeability, stimulating the growth and differentiation of intestinal epithelial cells. At the submucosal level: regulating the function of the innate and adaptive immune systems, inducing oral tolerance, and affecting the function of the enteric neuroendocrine system. Studies have shown that bifidobacteria in the host gut can promote the development and maturation of the infant immune system, and their species composition and diversity have received significant attention regarding their impact on allergic diseases.
In summary, food allergies are relatively common in infancy and have been increasing annually. Therefore, this study aims to understand the changes in the gut microbiota and its metabolites in infants with food allergies, as well as the differences in gut microbiota between children with and without immune tolerance to food allergies, and to discover related gut microbial metabolites.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Food-allergic children
Children diagnosed with food allergies
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both men and women;
* The child's legal guardian signed the informed consent to participate in the study.
* The legal guardian of the child commits to follow the study procedures and cooperate with the entire study process
Exclusion Criteria
* Associated with clinically significant abnormalities in liver and kidney function, nervous system, respiratory system, and coagulation function as determined by the investigator
* Unstable vital signs;
* Have other underlying medical conditions
* Individuals deemed unsuitable for this clinical trial.
1 Month
36 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GMSF-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.